Antonio Desmond McCarthy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6786278/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies. Journal of Bone and Mineral Research, 2010, 25, 211-221.	2.8	184
2	Advanced glycation endproducts interfere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. International Journal of Biochemistry and Cell Biology, 2004, 36, 840-848.	2.8	106
3	Metformin Reverts Deleterious Effects of Advanced Glycation End-Products (AGEs) on Osteoblastic Cells. Experimental and Clinical Endocrinology and Diabetes, 2008, 116, 333-340.	1.2	86
4	Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetologica, 2001, 38, 113-122.	2.5	78
5	Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Molecular and Cellular Biochemistry, 2003, 250, 1-10.	3.1	75
6	Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Molecular and Cellular Biochemistry, 1997, 170, 43-51.	3.1	68
7	Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: Preventive effects of metformin. Diabetes Research and Clinical Practice, 2013, 101, 177-186.	2.8	54
8	Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats. European Journal of Pharmacology, 2011, 668, 477-485.	3.5	52
9	Bone-Specific Alkaline Phosphatase Activity Is Inhibited by Bisphosphonates: Role of Divalent Cations. Biological Trace Element Research, 2005, 104, 131-140.	3.5	51
10	Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. European Journal of Pharmacology, 2008, 600, 140-147.	3.5	46
11	Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy. World Journal of Diabetes, 2016, 7, 122.	3.5	43
12	Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetologica, 1999, 36, 45-52.	2.5	40
13	Strontium ranelate stimulates the activity of bone-specific alkaline phosphatase: interaction with Zn2+ and Mg2+. BioMetals, 2014, 27, 601-607.	4.1	36
14	A simple method to assess the oxidative susceptibility of low density lipoproteins. BMC Clinical Pathology, 2001, 1, 1.	1.8	32
15	AGE-R3/galectin-3 expression in osteoblast-like cells: Regulation by AGEs. Molecular and Cellular Biochemistry, 2004, 266, 17-24.	3.1	30
16	Effects of a metabolic syndrome induced by a fructose-rich diet on bone metabolism in rats. Metabolism: Clinical and Experimental, 2014, 63, 296-305.	3.4	28
17	Characterization of Poly(ε-caprolactone)/Polyfumarate Blends as Scaffolds for Bone Tissue Engineering. Journal of Biomaterials Science, Polymer Edition, 2010, 21, 1297-1312.	3.5	27
18	Universal versus selective screening for the detection, control and prognosis of gestational diabetes mellitus in Argentina. Acta Diabetologica, 2010, 47, 97-103.	2.5	25

#	Article	IF	CITATIONS
19	Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells. European Journal of Pharmacology, 2014, 727, 8-14.	3.5	24
20	Non-enzymatic glycosylation of alkaline phosphatase alters its biological properties. Molecular and Cellular Biochemistry, 1998, 181, 63-69.	3.1	23
21	Strontium ranelate prevents the deleterious action of advanced glycation endproducts on osteoblastic cells via calcium channel activation. European Journal of Pharmacology, 2013, 706, 41-47.	3.5	18
22	Effects of fructose-induced metabolic syndrome on rat skeletal cells and tissue, and their responses to metformin treatment. Diabetes Research and Clinical Practice, 2017, 126, 202-213.	2.8	18
23	Evaluation of Strontium-Containing PCL-PDIPF Scaffolds for Bone Tissue Engineering: In Vitro and In Vivo Studies. Annals of Biomedical Engineering, 2019, 47, 902-912.	2.5	17
24	Advanced glycation end products and strontium ranelate promote osteogenic differentiation of vascular smooth muscle cells inÂvitro: Preventive role of vitamin D. Molecular and Cellular Endocrinology, 2017, 450, 94-104.	3.2	16
25	Morphological changes induced by advanced glycation endproducts in osteoblastic cells: Effects of co-incubation with alendronate. Acta Histochemica, 2013, 115, 649-657.	1.8	14
26	Multi-Scale Approach for the Evaluation of Bone Mineralization in Strontium Ranelate-Treated Diabetic Rats. Biological Trace Element Research, 2018, 186, 457-466.	3.5	7
27	Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells. BioMed Research International, 2016, 2016, 1-13.	1.9	4
28	Systemic oxidative stress in old rats is associated with both osteoporosis and cognitive impairment. Experimental Gerontology, 2021, 156, 111596.	2.8	4